Go Pro
NASDAQ:XNCR

Xencor Q4 2024 Earnings Report

Xencor logo
$23.80 -0.08 (-0.34%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$23.80 0.00 (-0.02%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xencor EPS Results

Actual EPS
-$0.62
Consensus EPS
-$0.81
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A

Xencor Revenue Results

Actual Revenue
$52.79 million
Expected Revenue
$17.14 million
Beat/Miss
Beat by +$35.66 million
YoY Revenue Growth
N/A

Xencor Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, February 27, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Xencor's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Xencor Earnings Headlines

Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
Contrasting Xencor (NASDAQ:XNCR) & Anika Therapeutics (NASDAQ:ANIK)
See More Xencor Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xencor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xencor and other key companies, straight to your email.

About Xencor

Xencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company that develops engineered antibodies and cytokine therapeutics for the treatment of cancer, autoimmune diseases and other serious medical conditions. The company’s platform is designed to modify antibody properties, including immune-system activation, half-life and biological activity, to create differentiated therapeutic candidates.

Xencor’s proprietary XmAb technology supports its internal research programs and collaborations with other biopharmaceutical companies. Its pipeline has included investigational medicines targeting immune and cancer-related pathways, including bispecific antibodies and cytokine-based therapies. The company has also licensed its antibody-engineering technology to external partners, contributing to the development of therapies based on XmAb designs.

Founded in 1997 and headquartered in Monrovia, California, Xencor serves global pharmaceutical and biotechnology markets through its research programs, licensing arrangements and strategic collaborations. The company’s leadership includes co-founder Bassil I. Dahiyat, who has served as president and chief executive officer and guides the company’s scientific and corporate development activities.

View Xencor Profile